Epidemiology and resistance of Achromobacter xylosoxidans from cystic fibrosis patients in Dijon, Burgundy: First French data

Journal of Cystic Fibrosis

Volumn 12, Issue 2, 2013, Pages 170-176

  Amoureux, Lucie ^a   Bador, Julien ^a   Siebor, Eliane ^a   Taillefumier, Nathalie ^a   Fanton, Annlyse ^a   Neuwirth, Catherine ^a  

^a DIJON UNIVERSITY HOSPITAL   (France)

Author keywords

Achromobacter xylosoxidans; Cystic fibrosis; DiversiLab; Genotyping; OXA 114; OXA 243; Resistance

Indexed keywords

CARBAPENEM DERIVATIVE; CEFTAZIDIME; CIPROFLOXACIN; ANTIINFECTIVE AGENT;

ACHROMOBACTER XYLOSOXIDANS; ADOLESCENT; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; CHILD; CYSTIC FIBROSIS; DISK DIFFUSION; DNA FINGERPRINTING; EPSILOMETER TEST; GENOTYPING TECHNIQUE; HUMAN; INFECTION RATE; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PRESCHOOL CHILD; PULSED FIELD GEL ELECTROPHORESIS; SCHOOL CHILD; SPUTUM CULTURE; ACHROMOBACTER DENITRIFICANS; FEMALE; FRANCE; GRAM-NEGATIVE BACTERIAL INFECTIONS; ISOLATION AND PURIFICATION; MALE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; POLYMERASE CHAIN REACTION;

ACHROMOBACTER DENITRIFICANS; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; DRUG RESISTANCE, BACTERIAL; ELECTROPHORESIS, GEL, PULSED-FIELD; FEMALE; FRANCE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; POLYMERASE CHAIN REACTION;

EID: 84878017563     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2012.08.005     Document Type: Article

References (28)

1. Beringer P.M., Appleman M.D. Unusual respiratory bacterial flora in cystic fibrosis: microbiologic and clinical features. Curr Opin Pulm Med 2000, 6:545-550.
2. Millar F.A., Simmonds N.J., Hodson M.E. Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985-2005. J Cyst Fibros 2009, 8:386-391.
3. Razvi S., Quittell L., Sewall A., Quinton H., Marshall B., Saiman L. Respiratory microbiology of patients with cystic fibrosis in the United States, 1995 to 2005. Chest 2009, 136:1554-1560.
4. Sawicki G.S., Rasouliyan L., Pasta D.J., Regelmann W.E., Wagener J.S., Waltz D.A., et al. The impact of incident methicillin resistant Staphylococcus aureus detection on pulmonary function in cystic fibrosis. Pediatr Pulmonol 2008, 43:1117-1123.
5. Waters V., Yau Y., Prasad S., Lu A., Atenafu E., Crandall I., et al. Stenotrophomonas maltophilia in cystic fibrosis: serologic response and effect on lung disease. Am J Respir Crit Care Med 2010, 183:635-640.
6. Hansen C.R., Pressler T., Nielsen K.G., Jensen P.O., Bjarnsholt T., Hoiby N. Inflammation in Achromobacter xylosoxidans infected cystic fibrosis patients. J Cyst Fibros 2010, 9:51-58.
7. Hogardt M., Ulrich J., Riehn-Kopp H., Tummler B. EuroCareCF quality assessment of diagnostic microbiology of cystic fibrosis isolates. J Clin Microbiol 2009, 47:3435-3438.
8. Kidd T.J., Ramsay K.A., Hu H., Bye P.T., Elkins M.R., Grimwood K., et al. Low rates of Pseudomonas aeruginosa misidentification in isolates from cystic fibrosis patients. J Clin Microbiol 2009, 47:1503-1509.
9. Burns J.L., Emerson J., Stapp J.R., Yim D.L., Krzewinski J., Louden L., et al. Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin Infect Dis 1998, 27:158-163.
10. Pereira R.H., Carvalho-Assef A.P., Albano R.M., Folescu T.W., Jones M.C., Leao R.S., et al. Achromobacter xylosoxidans: characterization of strains in Brazilian cystic fibrosis patients. J Clin Microbiol 2011, 49:3649-3651.
11. Emerson J., McNamara S., Buccat A.M., Worrell K., Burns J.L. Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008. Pediatr Pulmonol 2010, 45:363-370.
12. Ridderberg W., Bendstrup K.E., Olesen H.V., Jensen-Fangel S., Norskov-Lauritsen N. Marked increase in incidence of Achromobacter xylosoxidans infections caused by sporadic acquisition from the environment. J Cyst Fibros 2011, 10:466-469.
13. Kanellopoulou M., Pournaras S., Iglezos H., Skarmoutsou N., Papafrangas E., Maniatis A.N. Persistent colonization of nine cystic fibrosis patients with an Achromobacter (Alcaligenes) xylosoxidans clone. Eur J Clin Microbiol Infect Dis 2004, 23:336-339.
14. Van Daele S., Verhelst R., Claeys G., Verschraegen G., Franckx H., Van Simaey L., et al. Shared genotypes of Achromobacter xylosoxidans strains isolated from patients at a cystic fibrosis rehabilitation center. J Clin Microbiol 2005, 43:2998-3002.
15. Bador J., Amoureux L., Duez J.M., Drabowicz A., Siebor E., Llanes C., et al. First description of an RND-type multidrug efflux pump in Achromobacter xylosoxidans, AxyABM. Antimicrob Agents Chemother 2010, 55:4912-4914.
16. Duez J.M., Hadjait-Savioz M., Siebor E., Astruc K., Bador J., Pechinot A., et al. In vitro synergistic activity of combined piperacillin and tobramycin against clinical strains of Achromobacter xylosoxidans. J Chemother 2010, 22:139-141.
17. Doi Y., Poirel L., Paterson D.L., Nordmann P. Characterization of a naturally occurring class D beta-lactamase from Achromobacter xylosoxidans. Antimicrob Agents Chemother 2008, 52:1952-1956.
18. Turton J.F., Mustafa N., Shah J., Hampton C.V., Pike R., Kenna D.T. Identification of Achromobacter xylosoxidans by detection of the bla(OXA-114-like) gene intrinsic in this species. Diagn Microbiol Infect Dis 2011, 70:408-411.
19. Edwards U., Rogall T., Blocker H., Emde M., Bottger E.C. Isolation and direct complete nucleotide determination of entire genes. Characterization of a gene coding for 16S ribosomal RNA. Nucleic Acids Res 1989, 17:7843-7853.
20. Cheron M., Abachin E., Guerot E., el-Bez M., Simonet M. Investigation of hospital-acquired infections due to Alcaligenes denitrificans subsp. xylosoxydans by DNA restriction fragment length polymorphism. J Clin Microbiol 1994, 32:1023-1026.
21. Tenover F.C., Arbeit R.D., Goering R.V., Mickelsen P.A., Murray B.E., Persing D.H., et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995, 33:2233-2239.
22. De Baets F., Schelstraete P., Van Daele S., Haerynck F., Vaneechoutte M. Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance. J Cyst Fibros 2007, 6:75-78.
23. Lambiase A., Catania M.R., Del Pezzo M., Rossano F., Terlizzi V., Sepe A., et al. Achromobacter xylosoxidans respiratory tract infection in cystic fibrosis patients. Eur J Clin Microbiol Infect Dis 2011, 30:973-980.
24. Doleans-Jordheim A., Cournoyer B., Bergeron E., Croize J., Salord H., Andre J., et al. Reliability of Pseudomonas aeruginosa semi-automated rep-PCR genotyping in various epidemiological situations. Eur J Clin Microbiol Infect Dis 2009, 28:1105-1111.
25. Deplano A., Denis O., Rodriguez-Villalobos H., De Ryck R., Struelens M.J., Hallin M. Controlled performance evaluation of the DiversiLab repetitive-sequence-based genotyping system for typing multidrug-resistant health care-associated bacterial pathogens. J Clin Microbiol 2011, 49:3616-3620.
26. Jacquier H., Le Monnier A., Carbonnelle E., Corvec S., Illiaquer M., Bille E., et al. In vitro antimicrobial activity of "last-resort" antibiotics against unusual nonfermenting gram-negative bacilli clinical isolates. Microb Drug Resist 2012, 18:396-401.
27. Gibson R.L., Burns J.L., Ramsey B.W. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003, 168:918-951.
28. Ridderberg W., Wang M., Norskov-Lauritsen N. Multilocus sequence analysis of isolates of Achromobacter from patients with cystic fibrosis reveals infecting species other than Achromobacter xylosoxidans. J Clin Microbiol 2012, 50:2688-2694.